Lexicon Pharmaceuticals (LXRX) Research & Development (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Research & Development data on file, last reported at $12.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $12.8 million, down 16.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.6 million (down 31.42% YoY), and the FY2025 annual result was $61.1 million, down 27.65% from the prior year.
• Research & Development advanced to $12.8 million in Q1 2026 per LXRX's latest filing, from $11.3 million in the prior quarter.
• Over five years, Research & Development peaked at $26.7 million in Q4 2024 and troughed at $10.6 million in Q3 2022.
• A 5-year average of $15.9 million and a median of $14.8 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development surged 80.77% in 2024, then plunged 57.6% in 2025.
• A 5-year view of Research & Development shows it stood at $14.0 million in 2022, then gained by 5.62% to $14.8 million in 2023, then surged by 80.77% to $26.7 million in 2024, then sank by 57.6% to $11.3 million in 2025, then rose by 12.74% to $12.8 million in 2026.
• Business Quant data shows LXRX's Research & Development at $12.8 million in Q1 2026, $11.3 million in Q4 2025, and $18.8 million in Q3 2025.